These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18353972)

  • 21. A Novel Peptide Derived From Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization.
    Kim HK; Choi JS; Lee SW; Joo CK; Joe YA
    J Cell Biochem; 2017 May; 118(5):1132-1143. PubMed ID: 27618679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase.
    Chiu WC; Chiou TJ; Chung MJ; Chiang AN
    PLoS One; 2016; 11(8):e0161950. PubMed ID: 27579889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells.
    Li L; Zhang R; Fang ZY; Chen JN; Zhu ZL
    J Int Med Res; 2009; 37(2):426-37. PubMed ID: 19383237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor.
    Kaga T; Kawano H; Sakaguchi M; Nakazawa T; Taniyama Y; Morishita R
    Vascul Pharmacol; 2012 Aug; 57(1):3-9. PubMed ID: 22361334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
    Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
    PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1.
    Liu J; Razani B; Tang S; Terman BI; Ware JA; Lisanti MP
    J Biol Chem; 1999 May; 274(22):15781-5. PubMed ID: 10336480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells.
    Lee HJ; Kim SA; Lee HJ; Jeong SJ; Han I; Jung JH; Lee EO; Zhu S; Chen CY; Kim SH
    PLoS One; 2010 Aug; 5(8):e12358. PubMed ID: 20808805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor signaling pathway in endothelial cells is activated by BMPER to promote angiogenesis.
    Esser JS; Rahner S; Deckler M; Bode C; Patterson C; Moser M
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):358-67. PubMed ID: 25503991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.
    Yi T; Cho SG; Yi Z; Pang X; Rodriguez M; Wang Y; Sethi G; Aggarwal BB; Liu M
    Mol Cancer Ther; 2008 Jul; 7(7):1789-96. PubMed ID: 18644991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
    Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
    Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
    Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
    Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
    Sánchez-Arévalo Lobo VJ; Aceves Luquero CI; Alvarez-Vallina L; Tipping AJ; Viniegra JG; Hernández Losa J; Parada Cobo C; Galán Moya EM; Gayoso Cruz J; Melo JV; Ramón y Cajal S; Sánchez-Prieto R
    Biochem J; 2005 Apr; 387(Pt 1):231-8. PubMed ID: 15540985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.
    Legros L; Bourcier C; Jacquel A; Mahon FX; Cassuto JP; Auberger P; Pagès G
    Blood; 2004 Jul; 104(2):495-501. PubMed ID: 14976047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines.
    Bastaki M; Nelli EE; Dell'Era P; Rusnati M; Molinari-Tosatti MP; Parolini S; Auerbach R; Ruco LP; Possati L; Presta M
    Arterioscler Thromb Vasc Biol; 1997 Mar; 17(3):454-64. PubMed ID: 9102163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs.
    Pakneshan P; Birsner AE; Adini I; Becker CM; D'Amato RJ
    Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3909-13. PubMed ID: 18487370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.